Limiting Neurodegeneration in
Parkinson’s Disease
Parkinson’s disease is a
neurodegenerative disorder resulting in the loss of dopamine cells in the
substantia nigra, which is responsible for reward and movement in the brain.
Past research has incorporated L-DOPA, a dopamine precursor, that is used to
increase dopamine levels within the substantia nigra and also slow the
progression of stage one Parkinson’s disease. Researcher Ben Yang has a
different approach in his research paper review, Calcium, Cellular Aging, and Selective Neuronal Vulnerability in
Parkinson’s Disease. He believes that calcium entry into the cell through
the L-type calcium Cav 1.3 channel causes oxidative stress in the mitochondria,
which in turn create reactive oxygen species that trigger apoptosis in
mitochondrial cells (Yang). These reactive oxygen species are also responsible
for the dampening of ATP synthase and the mutations in mitochondrial DNA. When
too much calcium enters the cytoplasm, it can create an aggregation of Lewy
bodies within the endoplasmic reticulum indirectly or within the mitochondria
directly. This aggregation of alpha-synuclein proteins (Lewy bodies) prevent
the endoplasmic reticulum from undergoing proteostasis and restrict the
mitochondria from utilizing energy efficiently (Yang). Yang’s solution to
restrict the amount of calcium influx within the cell is to apply a
hypertensive drug called isradipine, which also blocks calcium channels.
Blocking calcium channels increases mitochondrial density in substantia nigra neurons,
which creates a lower turnover in dopamine cells, causing dopamine neurons to
age at a slower rate. Isradipine allows the substantia nigra mitochondria to
produce less energy expenditure and prevents the formation of reactive oxygen
species.
An article from ScienceDaily that
ties in with Yang’s research, identifies the alpha-synuclein protein formation
in brain cells and a way to block their action in the mammalian brain (John
Hopkins Medicine). Ted Dawson, the director of Cell Engineering at John Hopkins
School of Medicine, initially published evidence of alpha-synuclein spreading
from areas of lower brain structures including movement to areas of higher
reasoning and memory function. Building from this aggregation process, Dawson and
his research team cultured human brain cancer cells that prevented the
alpha-synuclein from entering the cell. The team then added genes to the
transmembrane receptors of these cancer cells to see which genes let in the
aggregates. Specifically, the transmembrane receptor called LAG3 bound to the
alpha-synuclein aggregates (John Hopkins Medicine). The team then created
knockout mice that lacked the LAG3 protein receptor and injected them with
alpha-synuclein aggregates and sure enough, the neurodegeneration of dopamine
neurons was limited by the mice antibodies. The mouse antibodies blocking
alpha-synuclein aggregation had similar effects in cultured cancerous human
cells and the antibodies are being tested in clinical trials. Thus, the
blocking of LAG3 protein can possibly slow the progression of Parkinson’s in
humans and be incorporated in chemotherapy, if the antibodies are approved in
clinical trials. It seems that Ben Yang’s proposition of isradipine application
to block L-type calcium channels aids in the durability of mitochondrial
substantia nigra cells. Substantia nigra cells could then use energy in the
form of ATP more efficiently and slow the formation of reactive oxygen species.
Dawson and his John Hopkins research team’s proposal could possibly eliminate
the formation of alpha synuclein aggregate. Both findings can play a part in
regulating the neurodegeneration of dopamine neurons in substantia nigra cells.
Works
Cited
Johns Hopkins Medicine. "New
treatment strategy could cut Parkinson's disease off at the pass." ScienceDaily. ScienceDaily, 29
September 2016. <www.sciencedaily.com/releases/2016/09/160929142756.htm>.
Ben Yang’s research review: https://luc.app.box.com/v/neuroscienceseminar/1/5783518889/93009542353/1
Journal Reference:
Ted M. Dawson et
al. Pathological α-synuclein transmission initiated by binding
lymphocyte- activation gene 3. Science,
September 2016 DOI:10.1126/science.aah3374